Score Overview
Explore the 2021 public Archive ranking →
Where AstraZeneca PLC has ranked, year by year
Showing 1 year ranking history by HDB Score.
Top 50 on HDB Score for 1 year, since 2021, through 2021.
- AZN
1998: 70.7% · 2021: 1.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-14 | $ 163.78 | — |
1 Year2025-09-12 | $ 156.43 | 4.70% |
5 Years2021-09-14 | $ 100.87 | 62.37% |
10 Years2016-09-14 | $ 50.06 | 227.20% |
20 Years2006-09-14 | $ 27.16 | 6x |
30 Years1996-09-13 | $ 8.22 | 19x |
All Time1993-05-17 | $ 2.98 | 55x |
| Period | Last Price2026-09-14 | 1 Year2025-09-12 | 5 Years2021-09-14 | 10 Years2016-09-14 | 20 Years2006-09-14 | 30 Years1996-09-13 | All Time1993-05-17 |
|---|---|---|---|---|---|---|---|
| Price | $ 163.78 | $ 156.43 | $ 100.87 | $ 50.06 | $ 27.16 | $ 8.22 | $ 2.98 |
| Return | — | 4.70% | 62.37% | 227.20% | 6x | 19x | 55x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 61.17B | $ 10.41B | $ 4.96B |
| 2025 | $ 58.73B | $ 10.25B | $ 5.74B |
| 2024 | $ 54.07B | $ 7.03B | $ 5.52B |
| 2023 | $ 45.81B | $ 5.95B | $ 5.86B |
| 2022 | $ 44.35B | $ 3.28B | $ 6.24B |
| 2021 | $ 37.41B | $ 112M | $ 6.39B |
| 2020 | $ 26.61B | $ 3.19B | $ 7.99B |
| 2019 | $ 24.38B | $ 1.33B | $ 6.21B |
| 2018 | $ 22.09B | $ 2.15B | $ 5.68B |
| 2017 | $ 22.46B | $ 3.00B | $ 4.55B |
| 2016 | $ 23.00B | $ 3.49B | $ 5.90B |
| 2015 | $ 24.70B | $ 2.82B | $ 6.85B |
| 2014 | $ 26.54B | $ 1.23B | $ 7.15B |
| 2013 | $ 25.80B | $ 2.55B | $ 10.01B |
| 2012 | $ 27.97B | $ 6.24B | $ 8.52B |
| 2011 | $ 33.59B | $ 9.91B | $ 11.81B |
| 2010 | $ 33.26B | $ 8.05B | $ 12.55B |
| 2009 | $ 32.80B | $ 7.52B | $ 11.42B |
| 2008 | $ 31.60B | $ 6.10B | $ 4.39B |
| 2007 | $ 29.55B | $ 5.59B | $ 6.04B |
| 2006 | $ 26.47B | $ 6.04B | $ 7.76B |
| 2005 | $ 23.95B | $ 4.70B | $ 6.60B |
| 2004 | $ 21.42B | $ 3.66B | $ 5.26B |
| 2003 | $ 18.84B | $ 3.03B | $ 3.95B |
| 2002 | $ 17.84B | $ 2.83B | $ 4.68B |
| 2001 | $ 16.48B | $ 4.15B | $ 5.46B |
| 2000 | $ 18.11B | $ 2.54B | $ 4.45B |
| 1999 | $ 15.13B | $ 1.14B | $ 3.28B |
| 1998 | $ 11.31B | $ 1.18B | $ 615M |
| 1997 | $ 8.58B | $ 1.20B | $ 1.20B |
| 1996 | $ 9.18B | $ 1.10B | $ 1.66B |
| 1995 | $ 7.56B | $ 519M | $ 1.22B |
| 1994 | $ 7.00B | $ 692M | $ 1.14B |
| IPO1993 | $ 6.56B | $ 637M | $ 1.55B |
AstraZeneca PLC fundamental performance
Between 2020 and 2025, revenue grew from $ 26.61B to $ 58.73B and net income grew from $ 3.19B to $ 10.25B. Revenue increased in every one of those 5 years; net income in every one.
Between 2015 and 2025, revenue grew from $ 24.70B to $ 58.73B and net income grew from $ 2.82B to $ 10.25B. Revenue increased in 8 of those 10 years; net income in 6.
AstraZeneca PLC currently holds a 20-year HDB Score of 4.5 out of 10. How the HDB Score is calculated.
Membership
Continue AZN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,827 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
